RSCI
Price
$0.07
Change
-$0.10 (-58.82%)
Updated
May 13 closing price
Capitalization
14.29M
SBFM
Price
$1.49
Change
-$0.02 (-1.32%)
Updated
Aug 15 closing price
Capitalization
6.79M
87 days until earnings call
Interact to see
Advertisement

RSCI vs SBFM

Header iconRSCI vs SBFM Comparison
Open Charts RSCI vs SBFMBanner chart's image
Redwood Scientific Technologies
Price$0.07
Change-$0.10 (-58.82%)
Volume$13.39K
Capitalization14.29M
Sunshine Biopharma
Price$1.49
Change-$0.02 (-1.32%)
Volume$26.68K
Capitalization6.79M
RSCI vs SBFM Comparison Chart in %
Loading...
RSCI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RSCI vs. SBFM commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RSCI is a Hold and SBFM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (RSCI: $0.07 vs. SBFM: $1.49)
Brand notoriety: RSCI and SBFM are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: RSCI: 100% vs. SBFM: 22%
Market capitalization -- RSCI: $14.29M vs. SBFM: $6.79M
RSCI [@Pharmaceuticals: Generic] is valued at $14.29M. SBFM’s [@Pharmaceuticals: Generic] market capitalization is $6.79M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RSCI’s FA Score shows that 0 FA rating(s) are green whileSBFM’s FA Score has 0 green FA rating(s).

  • RSCI’s FA Score: 0 green, 5 red.
  • SBFM’s FA Score: 0 green, 5 red.
According to our system of comparison, SBFM is a better buy in the long-term than RSCI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RSCI’s TA Score shows that 2 TA indicator(s) are bullish while SBFM’s TA Score has 4 bullish TA indicator(s).

  • RSCI’s TA Score: 2 bullish, 0 bearish.
  • SBFM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RSCI is a better buy in the short-term than SBFM.

Price Growth

RSCI (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while SBFM (@Pharmaceuticals: Generic) price change was +6.42% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Reported Earning Dates

SBFM is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RSCI($14.3M) has a higher market cap than SBFM($6.79M). RSCI YTD gains are higher at: -32.432 vs. SBFM (-50.337). RSCI has higher annual earnings (EBITDA): -143.71K vs. SBFM (-5.12M). SBFM has higher revenues than RSCI: SBFM (36.2M) vs RSCI (0).
RSCISBFMRSCI / SBFM
Capitalization14.3M6.79M211%
EBITDA-143.71K-5.12M3%
Gain YTD-32.432-50.33764%
P/E RatioN/A0.00-
Revenue036.2M-
Total CashN/A8.13M-
Total DebtN/A936K-
FUNDAMENTALS RATINGS
RSCI vs SBFM: Fundamental Ratings
RSCI
SBFM
OUTLOOK RATING
1..100
434
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
8664
P/E GROWTH RATING
1..100
10086
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RSCI's Valuation (38) in the null industry is in the same range as SBFM (40). This means that RSCI’s stock grew similarly to SBFM’s over the last 12 months.

RSCI's Profit vs Risk Rating (100) in the null industry is in the same range as SBFM (100). This means that RSCI’s stock grew similarly to SBFM’s over the last 12 months.

SBFM's SMR Rating (95) in the null industry is in the same range as RSCI (100). This means that SBFM’s stock grew similarly to RSCI’s over the last 12 months.

SBFM's Price Growth Rating (64) in the null industry is in the same range as RSCI (86). This means that SBFM’s stock grew similarly to RSCI’s over the last 12 months.

SBFM's P/E Growth Rating (86) in the null industry is in the same range as RSCI (100). This means that SBFM’s stock grew similarly to RSCI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RSCISBFM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
56%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
N/A
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RSCI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SBFM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RKDA4.650.25
+5.56%
Arcadia Biosciences
AMSC53.060.90
+1.73%
American Superconductor Corp
GSIT3.190.05
+1.59%
GSI Technology
EVGO3.810.04
+1.06%
EVgo
BBY71.63-0.11
-0.15%
Best Buy Company

RSCI and

Correlation & Price change

A.I.dvisor tells us that RSCI and ETST have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RSCI and ETST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RSCI
1D Price
Change %
RSCI100%
N/A
ETST - RSCI
22%
Poorly correlated
+7.89%
RAFA - RSCI
7%
Poorly correlated
+6.55%
SGIOF - RSCI
6%
Poorly correlated
+13.16%
TEVJF - RSCI
5%
Poorly correlated
N/A
SBFM - RSCI
5%
Poorly correlated
-1.33%
More

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and ELAN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
-1.33%
ELAN - SBFM
30%
Poorly correlated
-0.22%
TLRY - SBFM
29%
Poorly correlated
-12.71%
CGC - SBFM
26%
Poorly correlated
-12.75%
AQST - SBFM
25%
Poorly correlated
N/A
ACB - SBFM
25%
Poorly correlated
-5.75%
More